Product details
Background:
- Please choose product options by visiting DUOX1 rabbit pAb.
HMHA1 rabbit pAb
Ucallm_WP8899-50
Price range: $268.00 through $328.00
Specifications
| Size | 50μL/100μL |
| Target | ARHGAP45 |
| Reactivity | Human, Mouse |
| Applications | WB |
| MW(Calculated) | 125kD |
| MW(Observed) | |
| Host Species | Rabbit |
| Isotype | IgG |
| Conjugate/Modification | Unmodified |
| Recommended Dilution Ratio | WB 1:500-2000 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Storage | -15°C to -25°C/1 year(Do not lower than -25°C) |
| Concentration | 1 mg/ml |
| Clonality | Polyclonal |
| Clone Number | |
| Immunogen | Synthesized peptide derived from human HMHA1 |
| Specificity | This antibody detects endogenous levels of HMHA1 at Human, Mouse |
| Gene Name | HMHA1 KIAA0223 |
| Protein Name | Minor histocompatibility protein HA-1 [Cleaved into: Minor histocompatibility antigen HA-1 (mHag HA-1)] |
| Other Name | |
| Species | Human |
| Gene ID | 23526 |
| Uniprot | Q92619, |
| Species.1 | Mouse |
| Gene ID.1 | 70719 |
| Uniprot.1 | Q3TBD2 |
| Species.2 | |
| Gene ID.2 | |
| Uniprot.2 | |
| Cellular Localization | Cytoplasm . Cell projection, ruffle membrane . |
| Tissue Expression | Expressed on cells of the hematopoietic lineage. Detected in dendritic cells and epidermal Langerhans cells. Expressed in peripheral blood mononuclear cells, in all leukemia/lymphoma cell lines. Detected also in some solid tumors and tissues such as cancerous and non-cancerous tissue. |
| Signaling_pathway | |
| Research Areas | |
| Function | Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity.; Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL. |
Please login to post questions
Related products
